Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

Dr Murali Ramachandra, CEO of Aurigene Oncology, talks to Anju Ghangurde about the tough biotech funding environment, promising pipeline assets including a CAR-T cell therapy in Phase II and ‘hybrid’ manufacturing options, besides outcome-based reimbursement models. The promise of bispecifics and multispecifics in oncology, including Chinese biotech Akeso’s PD-1/VEGF bispecific antibody, are some of the other topics he discussed.